Recifercept
Phase 2Terminated 2 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Dec 24, 2021 → Mar 30, 2023
NCT ID
NCT05116046About Recifercept
Recifercept is a phase 2 stage product being developed by Pfizer for Achondroplasia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05116046. Target conditions include Achondroplasia.
What happened to similar drugs?
0 of 3 similar drugs in Achondroplasia were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05061277 | Phase 1 | Withdrawn |
| NCT05116046 | Phase 2 | Terminated |
| NCT04638153 | Phase 2 | Terminated |
| NCT04543344 | Phase 1 | Completed |
Competing Products
20 competing products in Achondroplasia